Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data
Abstract Background In January 2021, the United States (US) Food and Drug Administration (FDA) approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen for the treatment of HIV providing an alternative to daily oral regimens. We analyzed electronic health records (EHRs) to...
Saved in:
Main Authors: | Yiyang Liu, Rebecca J. Fisk-Hoffman, Maitri Patel, Robert L. Cook, Mattia Prosperi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | AIDS Research and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12981-024-00690-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084
by: Sinead Delany‐Moretlwe, et al.
Published: (2025-01-01) -
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data
by: Valentina Iannone, et al.
Published: (2025-01-01) -
Where authority, speech acts and modality meet: A pragmatic analysis of the trial record of King Charles I
by: Minako Nakayasu, et al.
Published: (2024-12-01) -
Impact of Combined Antiretroviral Treatment (cART) on Latent Cytomegalovirus Infection
by: Aura Temereanca, et al.
Published: (2025-01-01) -
Relationship Between Family Support and Adherence to Antiretroviral Medication in Patients with HIV at Bhayangkara Hospital, Indramayu, Indonesia
by: Wenny Nugrahati Carsita, et al.
Published: (2025-01-01)